ORIC Pharmaceuticals

OverviewSuggest Edit

ORIC is a pharmaceutical company dedicated to discovering and developing therapies towards overcoming resistance in cancer. It offers a small molecule antagonist of the glucocorticoid receptor, which has been implicated in resistance to various treatment modalities, including chemotherapy, immunotherapy, and anti-hormonal therapy, and across multiple cancers.

TypePublic
Founded2014
HQSouth San Francisco, CA, US
Websiteoricpharma.com

Latest Updates

Employees (est.) (Dec 2019)57
Job Openings10
Share Price (Sept 2021)$24.4(+2%)
Cybersecurity ratingAMore

Key People/Management at ORIC Pharmaceuticals

Jacob Chacko

Jacob Chacko

President, Chief Executive Officer and Board Member
Lori Friedman

Lori Friedman

Chief Scientific Officer
Pratik Multani

Pratik Multani

Chief Medical Officer
Matthew Panuwat

Matthew Panuwat

Chief Business Officer
Dominic Piscitelli

Dominic Piscitelli

Chief Financial Officer
Christian V. Kuhlen

Christian V. Kuhlen

General Counsel
Show more

ORIC Pharmaceuticals Office Locations

ORIC Pharmaceuticals has offices in South San Francisco and San Diego
South San Francisco, CA, US (HQ)
240 E Grand Ave
San Diego, CA, US
12526 High Bluff Dr #360
Show all (2)

ORIC Pharmaceuticals Financials and Metrics

ORIC Pharmaceuticals Revenue

USD

Net income (Q1, 2021)

(16.5m)

EBIT (Q1, 2021)

(16.6m)

Market capitalization (23-Sept-2021)

944.8m

Closing stock price (23-Sept-2021)

24.4

Cash (31-Mar-2021)

104.2m

EV

843.1m
ORIC Pharmaceuticals's current market capitalization is $944.8 m.
Annual
USDFY, 2020

General and administrative expense

13.4m

R&D expense

35.9m

Operating expense total

49.3m

EBIT

(74.2m)
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021

General and administrative expense

1.9m3.4m3.8m4.9m

R&D expense

7.3m7.7m8.8m11.7m

Operating expense total

9.2m11.1m12.6m16.6m

EBIT

(9.2m)(11.1m)(25.6m)(16.6m)
Annual
USDFY, 2020

Cash

78.4m

Prepaid Expenses

3.1m

Current Assets

296.7m

PP&E

2.0m
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021

Cash

79.4m196.6m62.0m104.2m

Prepaid Expenses

788.0k2.6m2.4m2.0m

Current Assets

80.2m199.2m189.1m280.1m

PP&E

2.1m2.0m1.9m2.0m
Annual
USDFY, 2020

Net Income

(73.7m)

Depreciation and Amortization

970.0k

Accounts Payable

4.3m

Cash From Operating Activities

(45.3m)
Quarterly
USDQ1, 2020Q2, 2020Q3, 2020Q1, 2021

Net Income

(8.9m)(19.9m)(45.4m)(16.5m)

Depreciation and Amortization

250.0k496.0k736.0k229.0k

Accounts Payable

(237.0k)1.4m2.3m(3.2m)

Cash From Operating Activities

(8.3m)(17.9m)(27.4m)(14.9m)
USDQ1, 2020

Financial Leverage

-0.9 x
Show all financial metrics

ORIC Pharmaceuticals Cybersecurity Score

Cybersecurity ratingPremium dataset

A

93/100

SecurityScorecard logo

ORIC Pharmaceuticals Online and Social Media Presence

Embed Graph

ORIC Pharmaceuticals News and Updates

ORIC Pharmaceuticals Announces Update on ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

SOUTH SAN FRANCISCO and SAN DIEGO, Sept. 21, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced an update on its CD73 inhibitor program. ORIC recen…

ORIC Pharmaceuticals Announces FDA Clearance of IND Application for ORIC-533, a Highly Potent, Orally Bioavailable Small Molecule CD73 Inhibitor

ORIC expects to initiate single agent clinical trial in an undisclosed tumor type in 2H21

ORIC Pharmaceuticals Reports Initial Clinical Data Being Presented at ASCO from Phase 1b Trial of ORIC-101 in Combination with Nab-Paclitaxel

Initial safety data showed combination regimen at the recommended Phase 2 dose was well tolerated; treatment-related adverse events primarily Grade 1 or 2, with no treatment-related discontinuations

ORIC Pharmaceuticals to Present at Jefferies Virtual Healthcare Conference

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 26, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, today announced that Jacob Chacko, M.D., chief executive offi…

ORIC Pharmaceuticals Presents Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

SOUTH SAN FRANCISCO and SAN DIEGO, April 12, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of resistance in cancer, presented four preclinical poster presentations at the 2021 American …

ORIC Pharmaceuticals Provides Corporate Update and Highlights Key 2021 Milestones

Lead program ORIC-101 continues patient enrollment investigating two therapeutic mechanisms of action and on track for two initial data readouts in 2021
Show more

ORIC Pharmaceuticals Blogs

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update

ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update Content Import Tue, 08/10/2021 - 16:05 ORIC Pharmaceuticals Reports Second Quarter 2021 Financial Results and Operational Update August 10, 2021 at 4:05 PM EDT This relea…

ORIC Pharmaceuticals to Host Conference Call with KOL to Review Initial Data Being Presented at ASCO from Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel

Webcast event scheduled for Wednesday, June 2, 2021, at 5:00 p.m. ET SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 25, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic

ORIC Pharmaceuticals Reports First Quarter 2021 Financial Results and Operational Update

Lead program ORIC-101 on track for two initial Phase 1b data readouts in 2021 Three IND/CTA filings for ORIC-533, -944, and -114 expected in 2021 SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, May 06, 2021 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting

ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination with Nab-paclitaxel at the 2021 ASCO Annual Meeting Content Import Wed, 04/28/2021 - 16:05 ORIC Pharmaceuticals to Present Initial Data from Ongoing Phase 1b Study of ORIC-101 in Combination…

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update

ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update Content Import Tue, 03/23/2021 - 16:05 ORIC Pharmaceuticals Reports Fourth Quarter and Full Year 2020 Financial Results and Operational Update March 23, 2021 at 4:05 PM ED…

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting

ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) Annual Meeting Content Import Wed, 03/10/2021 - 16:30 ORIC Pharmaceuticals to Present Posters on Four Programs at the 2021 American Association for Cancer Research (AACR) An…
Show more

ORIC Pharmaceuticals Frequently Asked Questions

  • When was ORIC Pharmaceuticals founded?

    ORIC Pharmaceuticals was founded in 2014.

  • Who are ORIC Pharmaceuticals key executives?

    ORIC Pharmaceuticals's key executives are Jacob Chacko, Lori Friedman and Pratik Multani.

  • How many employees does ORIC Pharmaceuticals have?

    ORIC Pharmaceuticals has 57 employees.

  • Who are ORIC Pharmaceuticals competitors?

    Competitors of ORIC Pharmaceuticals include Takeda Pharmaceutical, Celnova and Janssen Pharmaceuticals.

  • Where is ORIC Pharmaceuticals headquarters?

    ORIC Pharmaceuticals headquarters is located at 240 E Grand Ave, South San Francisco.

  • Where are ORIC Pharmaceuticals offices?

    ORIC Pharmaceuticals has offices in South San Francisco and San Diego.

  • How many offices does ORIC Pharmaceuticals have?

    ORIC Pharmaceuticals has 2 offices.